bipolar I disorder

Nov 17, 2026

Johnson & Johnson’s CAPLYTA Achieves Positive Results in Second Pivotal Phase 3 Bipolar Mania Study; US FDA Approves Klygefa for Adults with Generalised Myasthenia Gravis; Roche’s Gazyva/Gazyvaro Secures First FDA Approval for Primary Membranous Nephropathy; Summit Therapeutics Provides Regulatory Update on Ivonescimab BLA; Novo Submits Etavopivat for Regulatory Approval as a Once-Daily Treatment for Sickle Cell Disease

Mar 02, 2026

BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market

Apr 05, 2024

Vanda Broadens its Reach to Bipolar Disorder Treatment Market With Fanapt Approval

Newsletter/Whitepaper